ZimVie has announced its separation from Zimmer Biomet to focus on Dental and Spine product platforms and solutions.
ZimVie has announced its separation from Zimmer Biomet as an independent publicly traded company. ZimVie began this separation in 2021, and its common stock is now trading under the symbol “ZIMV” on the Nasdaq Stock Market. This was done after Zimmer Biomet announced its plan to split Dental and Spine businesses, according to President and CEO of ZimVie Vafa Jamali.
“As an independent company, we are uniquely poised to expand the reach of our Dental and Spine product platforms through innovation and enhanced commercial and operational focus,” Jamali said in a press release from the company. “Our solutions hold strong positions in the Dental and Spine markets, which represent a collective $20 billion addressable market opportunity. We intend to advance our positioning in each of these markets over time as we execute on multiple opportunities for growth and continue innovating to offer better solutions that help restore daily life.”
ZimVie also announced its Board of Directors including Vinit K. Asar, Sally Crawford, Vafa Jamali, David King, Richard Kuntz, and Karen Matusinec. Each director brings specific industry experience to the Board in its mission to improve growth and shareholder value.
This separation was finalized on March 1, 2022.